Eriko Tokunaga

Articles by Eriko Tokunaga

131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)

ByJavier Cortés, MD,Aditya Bardia, MD, MPH, FASCO,Kevin Punie,Carlos Barrios,Sara A. Hurvitz, MD,Andreas Schneeweiss, MD,Joohyuk Sohn,Eriko Tokunaga,Adam M. Brufsky, MD, PhD,Yeon Hee Park,Binghe Xu,Roberto Hegg,Mafalda Oliveira,Alessandra Fabi,Natalya Vaksman,Theresa Valdez,Xinrui Zhang,Catherine Lai, MD, MPH,Sara M. Tolaney, MD, MPH

138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer

ByErika P. Hamilton, MD,Giuseppe Curigliano,Miguel Martin, MD, PhD,Florence Lerebours,Junji Tsurutani,Marie-France Savard,Katarzyna J. Jerzak, MD, MSc, FRCPC,Xichun Hu,Luciana Carla Martins de Aquino Pimentel,Ciara C. O’Sullivan,Eriko Tokunaga,Alicia Okines,Chiun-Sheng Huang,William Jacot,Joohyuk Sohn,Eduardo Cronemberger Silva,Volkmar Mueller,Helene Viala,Shan Yang,Giovanna Granata,Qi Shen,Libero Santarpia,Veronique Dieras

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

ByAarti Chawla,Komal Jhaveri,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Philippe Aftimos,Cristina Saura,Joyce A. O’Shaughnessy,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Guiseppe Curigliano,Antonio Llombart-Cussac,Elgene Lim, MBBS, FRACP, PhD,María de la Luz García Tinoco,Joohyuk Sohn,Andre Mattar,Qingyuan Zhang,Chiun-Sheng Huang,Chih-Chiang Hung,Jorge Luis Martinez Rodriguez,Manuel Ruiz Borrego

Latest Updated Articles